• Javier Jacob, Òscar Miró, Carles Ferre, Carmen Borraz-Ordás, Guillermo Llopis-García, Rosa Comabella, José María Fernández-Cañadas, Amparo Mercado, Alex Roset, Fernando Richard-Espiga, Amparo Valero-Domènech, José Luis Martínez-Gimeno, Francisco Javier Martín-Sánchez, Pere Llorens, Pablo Berrocal-Gil, María José Pérez-Durá, José María Álvarez-Pérez, Pilar López-Díez, Pablo Herrero-Puente, and Josep Comín-Colet.
• Emergency Department and Short Stay Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
• Int. J. Clin. Pract. 2020 Oct 1; 74 (10): e13584.

IntroductionThe presence of iron deficiency (ID) in patients with acute heart failure (AHF) is high. There are few studies on the characteristics of these patients and the safety of ferric carboxymaltose administration (FCM).ObjectiveStudy the differences among patients with AHF based on the presence and type of ID as well as the safety of FCM administration in these patients.MethodThe AHF-ID study is a multicentre, analytical, prospective follow-up cohort including patients admitted to six Spanish hospitals for AHF. ID was defined as serum ferritin <100 μg/L (group A) or ferritin 100-299 μg/L with a TSAT <20% (group B). In cases receiving FCM the appearance of adverse events was analysed. Adjusted Cox regression was used to determine the association with 30-days reattendance for AHF after discharge.ResultsA total of 221 patients were recruited; 191 (86.4%) presented ID, 121 (63.4%) group A and 70 (36.6%) group B. There were scarce differences between the groups analysed. No differences were found in 30-days reattendance for AHF. FCM was administered to 158 (71.5%) patients, with 8 (5.1%) presenting adverse events, the most frequent being digestive alterations. Treatment was not discontinued in any case.ConclusionsThere are scarce differences between the presence and the type of ID in patients with AHF. The administration of FCM in patients with ID and AHF is safe.© 2020 John Wiley & Sons Ltd.

23 keywords...

hide…